Skip to Main Content
Contribute Try STAT+ Today

Covid-19 upended the way clinical trials get done — and don’t get done. With in-person visits on hold last year, drug companies jump-started a decade-old idea to enable trial participation from home. The momentum toward virtual, decentralized trials is continuing: Many drug companies are aiming to deploy digital devices like smartwatches and connected blood pressure cuffs to streamline data collection and develop new endpoints.

But often, the evidence behind those novel digital measures is far from solid. Before investing in outfitting study participants with a suite of at-home tech, pharma companies and regulators will want to see proof that a wearable or WiFi-connected device measures what it’s supposed to.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment